Our Opinion
NKGen Biotech Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
Company Description
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.
Company Website: https://www.nkgenbiotech.com